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Abstract
Background: Innovative trial designs are sought to streamline drug development in rare diseases. Basket- and
integrated protocol designs are two of these new strategies and have been applied in a handful oncologic trials.
We have taken the concept outside the realm of oncology and report about a first-in-human integrated protocol
design that facilitates the transition from phase Ia in healthy volunteers to phase Ib in patients with rare
complement-mediated disorders driven by the classical pathway.
Results: We have been conducting a prospective, double-blind, randomized, placebo-controlled first-in-human
study with TNT009, which is a humanized monoclonal antibody directed against the C1s subunit of human
complement component C1. The trial consisted of three subparts, including normal healthy volunteers
(part one and two) and a single cohort of patients in part three. Patients suffered from various
complement-mediated diseases sharing the same pathophysiological mechanism, i.e. bullous pemphigoid,
antibody-mediated rejection of organ transplants, cold agglutinin disease and warm autoimmune hemolytic
anemia. Primary objective of the trial has been to evaluate the safety and tolerability of TNT009 in humans.
Conclusions: This trial provides probably the first example that basket trials may not be limited to single
genetic aberrations, which is overly restrictive, but our trial design demonstrates that pathway specificity
is a viable paradigm for defining baskets. This will hopefully serve as a role model that could benefit other
innovative drug development programs targeting rare diseases.
Keywords: First-in-human trial, Basket design, Integrated protocol design, Orphan disease, Complement
pathway
Background
The definition and implementation of innovative trials
to accelerate access to efficacious and safe medicines is
of major interest to patients, industry and regulators [1].
On a European level, the Framework Programme 7 has
been supporting various multinational collaborative
efforts to develop new methodologies for making clinical
trials in rare diseases more efficient [2–4]. These trial
design strategies comprise, for example, integrated
protocol designs and another related emerging concept,
the basket trial design. Basket trials enroll patients with
multiple diseases and one (or more) drug targets in
cohorts or groups within one trial [5]. Thereby it is
possible to identify a potentially favorable response to
targeted therapy with a small number of patients [6].
Thus, basket designs have been successfully applied in a
handful oncologic trials dealing with rare cancers [7].
We have taken the concept of basket trial design
outside the realm of Oncology and have now developed
a first-in-human integrated protocol design that facili-
tates the transition from Phase Ia in normal healthy
volunteers (NHVs) to Phase Ib in patients with various
complement-mediated, orphan diseases in hematology,
transplant medicine and dermatology that share the
same molecular target for drug therapy.
Methods
Protocol design
The trial protocol was approved by the National Compe-
tent Authority and the Ethics Committee of the Medical
University of Vienna and is registered at ClinicalTrials.gov
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We have been conducting a prospective, double-blind,
randomized, placebo-controlled first-in-human study with
TNT009 which has recently received Orphan Drug desig-
nation by the European Medicines Agency for the treat-
ment of autoimmune hemolytic anemia. TNT009 is a
humanized monoclonal antibody directed against the C1s
subunit of human complement component C1 [8].
TNT009 is intended for treatment of the subset of
complement-mediated disorders that are driven by the
classical pathway (CP) [9]. The clinical development plan
is currently focused on different autoimmune diseases and
rejection of allografts. Antibody-mediated rejection trig-
gered by preformed or de novo donor-specific antibodies
is an important cause of graft dysfunction and loss [10].
There are several lines of experimental and clinical evi-
dence that activation of complement via the CP activation
substantially contributes to alloantibody-mediated tissue
damage [11]. Warm autoimmune hemolytic anemia has
an estimated prevalence of 2.3/10000. It can often be
managed with corticosteroids, splenectomy, or off-label
rituximab [12], which methods, however, are associated
with a relevant percentage of treatment failures, relapses,
and potentially severe adverse effects. Cold agglutinin
disease is an autoimmune hemolytic anemia with an
estimated prevalence of 0.3/10000. It is caused by IgM-
induced CP activation which is typically exacerbated by
exposure to cold environmental temperatures or viral
infections [13], for which no treatment is authorized.
Bullous pemphigoid is a serious autoimmune blistering
skin disease with a prevalence of 1/40000. It has a poor
long-term prognosis associated with serious co-morbidity
and increased mortality [14]. While bullous pemphigoid
can usually be successfully treated by steroids, their long
term use commonly leads to severe adverse events in the
elderly population.
Although the above seems to represent a clinical trial
population with a diverse set of clinical diagnoses, in fact
they are united by a common mechanism of disease
matched to the mechanism of action of TNT009.
Preceding in vitro studies where TNT009 was spiked
into blood samples drawn from patients confirmed the
strength of this linkage of pathobiology and pharma-
cology for each of these conditions.
The approved trial protocol has three sub-parts, which
have been conducted sequentially: part A, a single ascen-
ding dose trial in NHVs, part B, a multiple ascending dose
trial in NHVs, and part C, a multiple dose trial in patients
with various complement-mediated disorders as described
above. The route of administration, dose, and dosing inter-
val for TNT009 were based upon the corresponding non-
clinical safety, pharmacokinetic, and pharmacodynamic ob-
servations after administration to non-human primates
together with the findings from human in vitro pharmacol-
ogy studies (No Observed Adverse Effect Level (NOAEL)
of 100 mg/kg, first-in-human-dose, i.e. 1/300th of the
NOAEL, 0.3 mg/kg, threshold plasma level 10 μg/mL).
Part A has been conducted according to an ascending
dose cohort paradigm, in which a unique cohort of
NHVs has been treated at each single dose level. There
have been 7 cohorts of NHVs. NHVs in each cohort have
been randomly assigned to receive TNT009 or placebo.
In each cohort at least one participant has been treated
with placebo in order to preserve the blinded treatment
and to serve as control for the safety analysis.
The first two cohorts have consisted of 4 subjects
each, 3 given TNT009 (0.3 or 1 mg/kg) by intravenous
(IV) infusion, and 1 given placebo. The remaining 5 co-
horts have consisted of 8 subjects each, 6 given TNT009
by IV infusion (3, 10, 30, 60, or 100 mg/kg) and 2 given
placebo.
Not all subjects in a given cohort in part A have been
dosed on the same day: a sentinel pair (1 TNT009, 1
placebo) has been dosed on the first day, then staggered
groups of 2–3 per day thereafter. The sentinel pair of
subjects was incorporated into the design in the interest
of safety, i.e. to avoid exposing multiple subjects to any
given dose level before making an initial assessment of
early adverse events in one, and the single member of
this pair was treated with placebo in order to preserve
the blinded treatment.
There were no adverse or toxic effects seen in precli-
nical testing. So the probability for dose escalation based
on preclinical results was expected to be > 90 % for this
investigational monoclonal antibody. However, no
formal calculation of observed/expected dose-limiting
toxicity rates with respect to clinical decision-making
was involved.
Part B also has been conducted according to an ascen-
ding dose cohort paradigm. There have been 2 cohorts of
NHVs, each consisting of 8 subjects. These cohorts have
been given 4 weekly IV doses of TNT009 or placebo (6:2
active:placebo) at a dose level previously administered to
NHVs in the first part (30 or 60 mg/kg). Again, not all
subjects in the cohorts have been dosed on the same day:
a sentinel pair (1 TNT009, 1 placebo) has been dosed on
the first day, then staggered groups of 2–3 per day have
been dosed thereafter.
Part C is being conducted in a single cohort of patients.
All patients have received a single IV test dose of 10 mg/
kg followed by 4 weekly doses of 60 mg/kg (after 1–4
days). As expected for a trial in patients, patients have not
been started on the same day, because recruitment of
these rare patients with orphan diseases has been a grad-
ual process spanning a number of weeks (Table 1).
The primary endpoint of the trial has been the overall
safety and tolerability of TNT009 both in healthy volun
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No classical sample size estimation was performed.
However, a sample size of either 4 subjects (3 TNT009, 1
placebo) or 8 subjects (6 TNT009, 2 placebo) per dosing
cohort in part A, and 8 subjects (6 TNT009, 2 placebo)
per dosing cohort in part B is in compliance with the
standard 3 + 3 Phase 1 design [15]. In part C a sample size
of, for example, 10 patients for each disease group studied
allows for the estimation of an event rate of 30 % with
precision of ± 28.4 %. Thus, the target enrollment number
of patients for each of the specific complement-mediated
disease entities has been between 5 and 20 patients.
For statistical analyses data have been summarized by
dose cohort and, where appropriate, by visit. Descriptive
statistics will be provided for continuous variables.
Frequency counts and percentages will be presented for
categorical variables.
A two-sided significance level of 5 % has been applied
and two-sided 95 % confidence intervals have been
calculated.
Results and discussion
Basket trials have been developed as an efficient way of
screening experimental therapeutics across multiple pa-
tient populations in early-phase drug development. They
offer the possibility to include multiple molecularly de-
fined subpopulations in one cohesive design to evaluate
the targeted therapy in question [7]. So far, however, the
number of published trials is very limited. We reasoned
that such a study design would not only be suitable for
different rare diseases sharing a common genetic aberra-
tion but also acquired disease sharing a similar patho-
physiological mechanism that can be targeted by a
monoclonal antibody against a single target. In our trial
this is the subset of complement-mediated disorders that
are driven by the CP. There is a considerable gain in
efficiency by running multiple cohorts in this way, because
conducting a stand-alone trial within each cohort sepa-
rately would be more resource-, labor- and time-intensive
[7]. In order to maximize efficiency, we went further and
combined the objectives traditionally addressed in separ-
ate trials into a single study, applying an integrated proto-
col design for the transition of Phase Ia to Phase Ib within
one trial. The integration of these two components under
one protocol, at one study site, under one Principal Inves-
tigator was deemed most appropriate because this enabled
the most comprehensive and consistent evaluation of the
safety, pharmacokinetics (PK), and pharmacodynamics
(PD) of TNT009. Certainly, the primary and secondary
endpoints in this trial are analyses that encompass all sub-
jects- whether NHVs or patients- enrolled, profiling gen-
eral human safety and characterization of PK and PD.
Assessment of homogeneity, or comparison of aspects of
heterogeneity within NHVs with single or multiple dosing,
or between NHVs and patients with multiple dosing, are
highly relevant analyses that will inform subsequent
clinical development. It is conceivable that target-related
differences in PD, or disease-related differences in PK exist
for a novel biotherapeutic agent, and the basket design is
extraordinarily efficient at uncovering such differences.
Of the four diseases included in our study design, each
needs to be considered individually with respect to learn-
ing that informs subsequent clinical development. The
primary endpoint was defined as an assessment of safety
and overall tolerability for all participants including volun-
teers and different patient cohorts. Similarly, the key
secondary endpoints were defined as assessment of PK
and PD of TNT009 for all patient strata and healthy
volunteers. There is general agreement that safety, PK,
and PD in the target population comprise the sine qua
non deliverables of a Phase Ib clinical trial. Thereafter, in
Table 1 Trial design
SAD single ascending dose, MAD multiple ascending dose, MD multiple dose, NHV normal healthy volunteers, CAD cold agglutinin disease, wAIHA warm
agglutinin hemolytic anemia, BP bullous pemphigoid, AMR antibody mediated rejection
The number of patients will increase with further recruitment
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the hierarchy of value some disease strata emerge as
potentially more informative than others with regard to
the potential to achieve biomarker-based proof of mech-
anism or, better yet, clinical proof of concept (POC). In
the stratum of Cold Agglutinin Disease patients it was
anticipated that cessation of hemolysis and correction of
anemia could potentially be accessible endpoints within
the scope of the trial’s size and duration, provided that it
was possible to enroll patients with highly active disease
and that the effect of TNT009 was rapid and robust. On
the other hand, in the stratum of patients with antibody-
mediated rejection it was hoped that biomarker-based
proof of mechanism might be achieved by means of a gene
expression array (molecular microscopy). Since the path
to Phase II in such patients must traverse a Phase Ib safety
and PK/PD characterization in the target population, then
the hope for biomarker-based proof of mechanism repre-
sented “upside potential” added in to our Phase Ib design.
To generalize from our experience with this specific
pathway in these specific rare diseases, we believe that the
potential for biomarker-based proof of mechanism or
clinical POC is a relevant value-added; it could encourage
biopharma sponsors to consider profiling novel biothera-
peutic agents more broadly than they otherwise would
early in clinical development. Does this strategy provide a
universal “rule-in” or “rule-out” logic to such decision-
making? No, and indeed absence-of-evidence with respect
to early proof of mechanism or POC is not evidence-of-
absence. However, it does offer a pragmatic approach to
prioritization of target indications to pursue for larger-
scale clinical development, in that most sponsors will
choose to invest first in an indication where proof of
mechanism or POC has already been obtained. In this
sense our application of the basket trial paradigm allows
sponsors to “play the winner” and put the disease with
proof of mechanism or POC on the fast track for full
development at the earliest possible point in time.
However, new clinical trial designs such as this are not
without their limitations. In order for basket trials to
succeed some key preconditions must be fulfilled [6, 7],
the first of which being a strong scientific rationale for the
molecular marker-drug pairing [7] as in our case. Preclin-
ical tests revealed that TNT009 binds with high affinity
and specificity to C1s of humans in vitro and non-human
primates in vivo [8] and exhibited disease-relevant inhibi-
tory activity against the CP in a variety of in vitro disease
models. Pharmacology studies evaluating the effect of
TNT009 spiked into blood samples drawn from patients
with the diseases under investigation, confirmed the
strength of this linkage of pathobiology and pharmacology
for each of these diseases. Furthermore, reliable assays for
the marker of interest, complement system parameters
and disease-related biomarkers, exist and are well
established.
An integrated trial protocol must meet additional design
requirements, as outlined by the Clinical Trial Facilitation
Group (CTFG) of the Heads of Medical Agencies [16]; for
example, a pre-defined maximal dose and clear stopping
rules for dose escalation are necessary. For our trial we
established specific dose escalation criteria and timing to
allow progression between dose cohorts and implemented
a Data Safety Monitoring Board, consisting of a statisti-
cian, dermatologist, nephrologist, hematologist and inten-
sivist, for safety monitoring.
Protocol modifications to the ongoing study have been
made in amendments and independent approval for sub-
stantial amendments has been obtained from the Ethics
Committee. Data from literature suggest that it is not un-
common to have three to five protocol amendments after
the initiation of a clinical trial [17]. The adaptive approach
might result in a higher number of substantial amen-
dments, which theoretically might cause operational bias
that would be relevant for pivotal clinical trials. However,
the currently running Phase Ia/Ib trial is focused on safety
and POC and not a pivotal Phase III trial.
Statistical considerations will continue to play a central
role in basket and integrated trial designs [18, 19]. To
avoid pitfalls, we established a statistical analysis plan
with a detailed protocol. For part A and B, sample size
was calculated using an adapted 3 + 3 phase I design for
dose escalation [15]. In part C the sample size was dete-
rmined by the likely number of available patients with
those orphan diseases. Further justification was given by
calculation of the detectable adverse event rates. This is
in line with recently published recommendations for
Phase I studies in Oncology or rare diseases [17, 19].
Finally, as mentioned above, we applied an independent
data safety monitoring board to ensure quality, validity
and integrity of the collected data [15, 17, 18].
Conclusion
In conclusion, we believe that based on a strong scientific
rationale and in accordance with the guidelines published
[15, 16], the application of new innovative trial designs in
a non-oncologic environment will combine safety for the
patients with increased operational efficiency. This may
streamline the development of new compounds in rare
diseases, perhaps especially in Europe, where the regula-
tory climate is conducive to the conduct of such trials.
Abbreviations
CP, classical pathway; CTFG, Clinical Trial Facilitation Group; NHV, Normal





Writing of this manuscript was supported by a grant from the European
Union: ASTERIX Health-FP-2013-603160, Seventh Framework Programme.
Derhaschnig et al. Orphanet Journal of Rare Diseases  (2016) 11:134 Page 4 of 5
Availability of data and material
Not applicable. Protocol can be found at https://clinicaltrials.gov (NCT
02502903).
Authors’ contributions
BJ and JG conceived of the study. JG, UJ, GS, GB and BJ participated in the
design and conception of the study. UD, UJ, GS, GB and BJ have been
conducting the trial at the study site. UD and BJ drafted the manuscript.
All authors read and approved the final manuscript.
Competing interests
Jim Gilbert is employee of True North Therapeutics. The authors declare that
they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The Trial was approved by the national Competent Authority and the Ethics
Committee of the Medical University of Vienna. All participants signed
written informed consent before any trial related intervention.
Author details
1Department of Clinical Pharmacology, Medical University of Vienna,
Währinger Gürtel 18-20, 1090 Vienna, Austria. 2Department of Emergency
Medicine, Medical University of Vienna, Vienna, Austria. 3True North
Therapeutics, San Francisco, CA, USA. 4Department of Internal Medicine I,
Division of Haematology, Medical University of Vienna, Vienna, Austria.
5Department of Internal Medicine III, Division of Nephrology and Dialysis,
Medical University of Vienna, Vienna, Austria. 6Department of Dermatology,
Division of Immunology, Allergy and Infectious Diseases, Medical University
of Vienna, Vienna, Austria.
Received: 11 May 2016 Accepted: 28 July 2016
References
1. Goldman M, Seigneuret N, Eichler H-G. The Innovative Medicines Initiative:
an engine for regulatory science. Nat Rev Drug Discov. 2015;14(1):1–2.
2. Asterix. http://www.asterix-fp7.eu. Accessed April 2016.
3. Inspire. http://www2.warwick.ac.uk/fac/med/research/hscience/stats/
currentprojects/inspire. Accessed April 2016.
4. Ideas.http://www.appliedclinicaltrialsonline.com/ideas-initiative. Accessed
April 2016.
5. Menis J, Hasan B, Besse B. New clinical research strategies in thoracic
oncology: clinical trial design, adaptive, basket and umbrella trials, new
end-points and new evaluations of response. Eur Respir Rev.
2014;23(133):367–78.
6. Redig AJ, Janne PA. Basket trials and the evolution of clinical trial design in
an era of genomic medicine. J Clin Oncol Off J Am Soc Clin Oncol.
2015;33:975–7.
7. Mandrekar SJ, Dahlberg SE, Simon R. Improving Clinical Trial Efficiency:
Thinking outside the Box. Am Soc Clin Oncol Educ Book.
2015;e141–7.
8. Shi J, Rose EL, Singh A, Hussain S, Stagliano NE, Parry GC, et al. TNT003,
an inhibitor of the serine protease C1s, prevents complement activation
induced by cold agglutinins. Blood. 2014;123(26):4015–22.
9. Morgan BP, Harris CL. Complement, a target for therapy in inflammatory
and degenerative diseases. Nat Rev Drug Discov. 2015;14(12):857–77.
10. Loupy A, Lefaucheur C, Vernerey D, Prugger C, van Huyen Duong J-P,
Mooney N, van Huyen J-P D, Mooney N, et al. Complement-binding anti-
HLA antibodies and kidney-allograft survival. N Engl J Med.
2013;369(13):1215–26.
11. Stegall MD, Chedid MF, Cornell LD. The role of complement in antibody-
mediated rejection in kidney transplantation. Nat Rev Nephrol.
2012;8(11):670–8.
12. Roumier M, Loustau V, Guillaud C, Languille L, Mahevas M, Khellaf M, et al.
Characteristics and outcome of warm autoimmune hemolytic anemia in
adults: New insights based on a single-center experience with 60 patients.
Am J Hematol. 2014;89(9):E150–5.
13. Berentsen S. Complement, cold agglutinins, and therapy. Blood. 2014;
123(26):4010–2.
14. Daniel BS, Borradori L, Hall 3rd RP, Murrell DF. Evidence-based management
of bullous pemphigoid. Dermatol Clin. 2011;29(4):613–20.
15. U.S. Food and Drug Administration (FDA). Available from: www.fda.gov/
BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/
Guidances/Vaccines/ucm182443.htm#3. Accessed April 2016.




17. Chow S-C, Chang M. Adaptive design methods in clinical trials - a review.
Orphanet J Rare Dis. 2008;3:11.
18. Chow S-C, Corey R. Benefits, challenges and obstacles of adaptive clinical
trial designs. Orphanet J Rare Dis. 2011;6:79.
19. Dahlberg SE, Shapiro GI, Clark JW, Johnson BE. Evaluation of statistical
designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer
Center experience. J Natl Cancer Inst. 2014;106(7). doi:10.1093/jnci/dju163.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Derhaschnig et al. Orphanet Journal of Rare Diseases  (2016) 11:134 Page 5 of 5
